Zafgen to Present at the Cowen & Company 36th Annual Health Care Conference

MyoKardia to Present at Cowen and Company 36th Annual Health Care Conference

Foundation Medicine to Present at Cowen and Company\'s 36th Annual Healthcare Conference

Global Blood Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference

Voyager Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

Zafgen Joins NORD in Raising Awareness of Rare Disease Day

Sage Therapeutics to Present at the Cowen & Co. 36th Annual Health Care Conference

bluebird bio Announces Transition of Chief Financial Officer

Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCOREâ„¢ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers

bluebird bio Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Operational Progress

Sage Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results

Neon Therapeutics Enters Collaborative Research Agreement with the Netherlands Cancer Institute

MyoKardia Announces Transition of Chief Medical Officer

Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook

Third Rock Ventures Launches Pliant Therapeutics with $45 Million Series A to Treat Fibrotic Diseases

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

Zafgen\'s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint

bluebird bio Announces First Patient Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Neon Therapeutics Enters License Agreement with Sanquin for Peptide-MHC Assay Technology

Sage Therapeutics to Report Fourth Quarter and Full Year 2015 Financial Results on Wednesday, February 24, 2016

Blueprint Medicines to Present at RBC Capital Markets 2016 Global Healthcare Conference

Zafgen to Participate in Upcoming Investor Conferences

Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Global Blood Therapeutics Announces Changes to Board of Directors

Blueprint Medicines Appoints Lonnel Coats to Board of Directors

MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy

Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2015 Financial Results and Conference Call

Agios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10

Sage Therapeutics to Present at the 2016 Leerink Global Healthcare Conference

Foundation Medicine to Present at the Leerink Global Healthcare Conference

Editas Medicine Announces Pricing of Initial Public Offering

Voyager Therapeutics Promotes Jeff Goater to Chief Financial Officer

Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors

Albumedix and Eleven Biotherapeutics Announce Albumin Variant Technology Agreement

Jounce Therapeutics Appoints Perry Karsen to its Board of Directors

CytomX Announces Third Target Selection by Bristol-Myers Squibb, Triggering Milestone

Zafgen\'s Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints

Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis

Foundation Medicine, Horizon Healthcare Services, Inc. and COTA Collaborate to Demonstrate the Benefits of a Precision Medicine Treatment Approach for Patients with Metastatic Non-Small Cell Lung Cancer

Agios Outlines Key 2016 Goals and Priorities

Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay

Sanofi and Warp Drive Bio to Collaborate on the Development of Novel Oncology Therapies and Antibiotics Based on Proprietary Platforms

Allena Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference

Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity

Alcresta Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference

Global Blood Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference

bluebird bio to Present at the 34th Annual J.P. Morgan Healthcare Conference

Blueprint Medicines Strengthens Executive Leadership Team